Capsule-based vaccine to protect against Klebsiella infections
Official title: A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
Funded at Vaxnewmo, LLC · NIH-11399773 · Data updated 2026-11-12
A new capsule-based vaccine aimed at preventing Klebsiella pneumoniae infections in people, including children, by using a cutting-edge bioconjugation method.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaxnewmo, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | January 1, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $999,022 |
| NIH project number | 5R44AI167078-04 |
| Project ID | NIH-11399773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for Klebsiella infections, including young children and patients in healthcare settings.
✕Less likely to help
Some individuals with differing immune responses or contraindications to vaccines may not benefit.
What this research studies
This project aims to develop a multivalent vaccine that targets Klebsiella pneumoniae’s capsule to prevent disease and death. It uses a novel bioconjugation platform to link polysaccharides to a carrier protein, potentially simplifying manufacturing. The approach builds on prior data suggesting vaccination could reduce illness across age groups, including kids. The work involves preclinical studies using animal models to demonstrate immune responses and protective effects. If successful, it could lead toward clinical testing and eventual vaccination options for patients at risk.
Why it matters
Potential benefit: If successful, the vaccine could reduce Klebsiella infections and antibiotic resistance-related mortality.
How similar studies have gone: Previous work with polysaccharide-protein conjugate vaccines has shown protection against similar pathogens, supporting a path forward for this approach.
Where this research is happening
-
Vaxnewmo, LLC
Saint Louis, United States Active
Researchers
- Principal investigator: Harding, Christian — Vaxnewmo, LLC
- Study coordinator: Harding, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.